Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.

Detalles Bibliográficos
Autores principales: Eliakim-Raz, Noa, Massarweh, Amir, Stemmer, Amos, Stemmer, Salomon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358809/
https://www.ncbi.nlm.nih.gov/pubmed/34379092
http://dx.doi.org/10.1001/jamaoncol.2021.4390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358809/
https://www.ncbi.nlm.nih.gov/pubmed/34379092
http://dx.doi.org/10.1001/jamaoncol.2021.4390

Ejemplares similares